SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
187 hedge funds and large institutions have $630M invested in SANGAMO THERAPEUTICS INC in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 65 increasing their positions, 54 reducing their positions, and 29 closing their positions.
59% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $14.2M
20% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 54
1.73% more ownership
Funds ownership: 62.78% → 64.51% (+1.7%)
5% less funds holding
Funds holding: 197 → 187 (-10)
14% less capital invested
Capital invested by funds: $729M → $630M (-$99M)
34% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 29
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.1M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$13.9M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$13.3M |
| 4 |
Renaissance Technologies
New York
|
+$9.25M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$8.18M |
| 4 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$6.98M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.74M |
SGMO Hedge Fund Activity: Q1 2019 in Review
187 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2019, worth a combined $630M — down 14% from $729M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SGMO and 19 opened new positions — a net loss of 10 holders — while 54 trimmed existing stakes and 65 added.
The largest buyer was Wellington Management Group, adding an estimated $23.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $13.6M sold.
- 187 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2019, down from 197 in Q4 2018.
- Funds reported $630M of SANGAMO THERAPEUTICS INC stock for Q1 2019, down 14% quarter-over-quarter.
- 19 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2019 and 29 closed out, a net change of -10 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2019 was Wellington Management Group, an estimated $23.1M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2019 was EcoR1 Capital, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2019.